Roche Holding AG Digitalisation Day Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Harry MacKinnon Gillis - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Great presentation. So I just wanted to ask how you think about measuring returns on your digital investments or your AI investments. So for example, I can imagine this is a lot easier for some of the maybe -- the supply chain processes versus the earlier stage R&D work. And then, I guess, thinking about the R&D investments, will it really just take time until we see some of these drugs discovered by AI until they ultimately reach the clinic to be able to assess sort of the returns on these investments, how that ultimately plays out? And then related just given sort of the breadth of exciting opportunities and capabilities you've highlighted. I was just wondering how you make sure that you continue to spend on the right programs and capabilities? And I guess, if the scientists are going to the CFO with all these amazing projects, sort of what processes are in place to maybe hold that back and ensure that the money spent wisely?